| |
 |
| Publications |
 |
Renal effects of contrast media in diabetic patients undergoing
diagnostic or interventional coronary angiography
Kathy J. Hardiek, Richard E. Katholi, Randall S. Robbs, Charles E. Katholi |
|
Stent Thrombosis Rates Increase Over Time
referencing Gregory J. Mishkel, MD |
|
Drug-Eluting Stent Thrombosis Rate
Suggests Acceleration Over Time
referencing Gregory J. Mishkel, MD |
|
Highlights of the Year in JACC 2007
referencing Gregory J. Mishkel, Anna L. Moore, Steve Markwell, M. Coleman Shelton, and Marc E. Shelton. |
|
Short- and Long-Term Clinical Outcomes of Coronary DrugEluting Stent Recipients Presenting with Chronic Renal Disease *
by Gregory J. Mishkel, MD, Joji J. Varghese, MD, Anna L. Moore, MPH, Frank Aguirre, MD, Stephen J. Markwell, MS, Marc Shelton, MD |
|
Long-Term Outcomes After Management of Restenosis or Thrombosis of Drug-Eluting Stents *
by Gregory J. Mishkel, Anna L. Moore, Steve Markwell, M. Coleman Shelton and Marc E. Shelton |
|
Bivalirudin versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Drug-Eluting Stent Implantations in the Absence of Acute Myocardial Infarction: Clinical and Economic Results *
by
Gregory J. Mishkel, MD, Anna L. Moore, MPH, Stephen J. Markwell, MA, and Robert W. Ligon, MS |
|
Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial *
by Mark A. Turco, John A. Ormiston, Jeffrey J. Popma, Lazar Mandinov, Charles D. O’Shaughnessy, Tift Mann, Thomas F. McGarry, Chiung-Jen Wu, Charles Chan, Mark W.I. Webster, Jack J. Hall, Gregory J. Mishkel, Louis A. Cannon, Donald S. Baim, and Joerg Koglin |
|
Contrast-induced Nephropathy -
Update and
Practical Clinical Applications *
by Richard E Katholi,MD |
|
Performance Goals and Endpoint Assessments for Clinical Trials of Femoropopliteal Bare Nitinol Stents in Patients With Symptomatic Peripheral Arterial Disease *
by Dr. Krishna J. Rocha-Singh |
| |
|
| |
*Adobe Reader required.
 |
|
|
|
|
